Angiotensin-converting enzyme inhibitors and receptor blockers usage in covid-19 illness leading to confusion or conclusion: A comprehensive review
作者： M. Chandramouli , S. Doddamani , S. Ningaiah
DOI:
关键词:
摘要: In the present situation, consequence of Angiotensin-Converting Enzyme inhibitors (ACEi) and Angiotensin Receptor Blockers (ARB) is being questioned since its usage has increased progressively due to significance in medical field as lifesaving drugs associated with cardiovascular diseases renal failure The novel study these by researchers all around world showing varied opinions Hence, above-inhibitors COVID-19 patients reviewed, also discussing pharmacological importance This review about coronavirus's efficiency develop hosts who are regular treatment ACEi ARB Besides, there a detailed mechanism attack on host, which reviewed gives brief idea adopted for conventional approaches It ACEi/ARB believed this particularly will help give clear treating already suffering from disease further considering use categorize it threat or not © 2020 authors
参考文章(76)
Ying-Ying Zheng, Yi-Tong Ma, Jin-Ying Zhang, Xiang Xie, COVID-19 and the cardiovascular system. Nature Reviews Cardiology. ,vol. 17, pp. 259- 260 ,(2020) , 10.1038/S41569-020-0360-5
Haibo Zhang, Josef M. Penninger, Yimin Li, Nanshan Zhong, Arthur S. Slutsky, Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Medicine. ,vol. 46, pp. 586- 590 ,(2020) , 10.1007/S00134-020-05985-9
Kenji Mizumoto, Katsushi Kagaya, Alexander Zarebski, Gerardo Chowell, Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Eurosurveillance. ,vol. 25, pp. 2000180- ,(2020) , 10.2807/1560-7917.ES.2020.25.10.2000180
Lisheng Wang, Yiru Wang, Dawei Ye, Qingquan Liu, Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence. International Journal of Antimicrobial Agents. ,vol. 55, pp. 105948- ,(2020) , 10.1016/J.IJANTIMICAG.2020.105948
Bo Li, Jing Yang, Faming Zhao, Lili Zhi, Xiqian Wang, Lin Liu, Zhaohui Bi, Yunhe Zhao, Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clinical Research in Cardiology. ,vol. 109, pp. 531- 538 ,(2020) , 10.1007/S00392-020-01626-9
Tian-Yuan Xiong, Simon Redwood, Bernard Prendergast, Mao Chen, Coronaviruses and the cardiovascular system: acute and long-term implications. European Heart Journal. ,vol. 41, pp. 1798- 1800 ,(2020) , 10.1093/EURHEARTJ/EHAA231
Junyi Guo, Zheng Huang, Li Lin, Jiagao Lv, Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Journal of the American Heart Association. ,vol. 9, ,(2020) , 10.1161/JAHA.120.016219
Guohua Zeng, Jian Wang, Bo Zhang, Jianquan Hou, Wei Zhang, Daojun Lv, Di Gu, Weidong Chen, Rui Chen, Shancheng Ren, Xiyi Wei, Chao Qin, Yu-Tian Xiao, Yue Yang, Ninghong Song, Sex Differences in Severity and Mortality Among Patients With COVID-19: Evidence from Pooled Literature Analysis and Insights from Integrated Bioinformatic Analysis arXiv: Populations and Evolution. ,(2020)
Jun Lan, Jiwan Ge, Jinfang Yu, Sisi Shan, Huan Zhou, Shilong Fan, Qi Zhang, Xuanling Shi, Qisheng Wang, Linqi Zhang, Xinquan Wang, Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. ,vol. 581, pp. 215- 220 ,(2020) , 10.1038/S41586-020-2180-5
Robert C Speth, Keep taking your ACE inhibitors and ARBs during the COVID 19 pandemic. Journal of Travel Medicine. ,vol. 27, ,(2020) , 10.1093/JTM/TAAA045